Abstract
A "microbrachytherapy" was developed as treatment option for inoperable tumours by direct intratumoral injection of radioactive holmium-166 ( 166 Ho) microspheres (MS). 166 Ho emits β-radiation which potentially enables a high, ablative, radioactive-absorbed dose on the tumour tissue while sparing surrounding tissues. Safety and efficacy of 166 Ho microbrachytherapy were evaluated in a prospective cohort study of 13 cats with inoperable oral squamous cell carcinoma without evidence of distant metastasis. Local response rate was 55%, including complete response or partial response (downstaging) enabling subsequent marginal resection. Median survival time was 113 days overall, and 296 days for patients with local response. Side effects were minimal. Tumour volume was a significant predictor of response. Response rate may be further improved by optimizing the intratumoral spatial distribution of 166 Ho MS. 166 Ho microbrachytherapy has potential as a minimally invasive, single procedure radio-ablation treatment of unresectable tumours with minimal morbidity.
Highlights
Background & AimsA “microbrachytherapy” was developed as treatment option for inoperable tumours by direct intratumoral injection of radioactive holmium-166 (166Ho) microspheres (MS).Department of Radiology and Nuclear medicine, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Oral and MaxillofacialSurgery, University Medical Center Utrecht, Department of Head and Neck SurgicalOncology, UMC Utrecht Cancer Center, Ho emits β-radiation which potentially enables a high, ablative, radioactive-absorbed dose on the tumour tissue while sparing surrounding tissues
Ho microbrachytherapy were evaluated in a prospective cohort study of 13 cats with inoperable oral squamous cell carcinoma without evidence of distant metastasis
The incidence of OSCC has increased with 1.8%
Summary
Local response rate was 55%, including complete response or partial response (downstaging) enabling subsequent marginal resection.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
